by OTMS Staff | Aug 26, 2026 | PatentVest Pulse
PatentVest Pulse Who's Actually Building the AI in AI Smart Glasses? Patent filings reveal who is really building the technology behind this category — and the answer includes companies that don't sell glasses at all. PV Pulse Report Key Takeaways Meta isn't just...
by OTMS Staff | Jul 21, 2026 | PatentVest Pulse
PatentVest Pulse — What Is OpenAI Actually Patenting? PatentVest Pulse What Is OpenAI Actually Patenting? A PatentVest Pulse analysis of OpenAI’s patent portfolio July 2026 OpenAI's patents tell a story that goes far beyond ChatGPT. Rather than protecting the...
by OTMS Staff | Jun 26, 2026 | PatentVest Pulse
PatentVest Pulse — The Crossover PatentVest Pulse The Crossover How FGF21 Became the Cardiometabolic Layer Beneath GLP-1 Beyond GLP-1 Series, Report #6 of 12 | June 2026 Key Takeaways The next $10.7 billion opportunity isn't another GLP-1.Three pharmaceutical...
by OTMS Staff | Jun 2, 2026 | PatentVest Pulse
PatentVest Pulse — The Muscle ProblemPATENTVEST PULSEThe Muscle Problem: How Myostatin Could Expand the GLP-1 OpportunityBeyond GLP-1 Series, Report #5 of 12 | June 2026 Key Takeaways The next obesity opportunity may not be another GLP-1. Twenty programs are building...
by OTMS Staff | Apr 23, 2026 | PatentVest Pulse, Uncategorized
PatentVest Pulse — The Triple-Agonist RacePatentVest PulseThe Triple-Agonist RaceRetatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market.April 2026Ozempic and Wegovy built a $50B market with 15% weight loss. Mounjaro and Zepbound...
by OTMS Staff | Mar 25, 2026 | PatentVest Pulse
PatentVest Pulse — The Amylin RenaissancePATENTVEST PULSEThe Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity MedicineReport #2 | March 2026GLP-1 receptor agonists built a $71 billion market by making patients...
Recent Comments